MDT Q2 2026

Q4 2026 Q3 2026 Q2 2026 Q1 2026 Q4 2025

Earnings

Medtronic posted a convincingly strong fiscal second quarter for 2026, with revenue climbing 6.6% year-over-year to $8.96 billion against a consensus estimate of $8.86 billion, while non-GAAP diluted EPS of $1.36 beat the $1.31 Wall Street consensus … Read more Medtronic posted a convincingly strong fiscal second quarter for 2026, with revenue climbing 6.6% year-over-year to $8.96 billion against a consensus estimate of $8.86 billion, while non-GAAP diluted EPS of $1.36 beat the $1.31 Wall Street consensus by 3.49%, underscoring broad-based momentum across the company's portfolio. The standout driver was the Cardiovascular segment, which delivered its best reported growth in over a decade, rising 10.8% to $3.44 billion, fueled by an explosive 71% surge in Cardiac Ablation Solutions as the company's pulsed field ablation technology gained rapid adoption, including 128% growth in the U.S. Alone. Barclays responded by lifting its price target on Medtronic to $111, maintaining an Overweight rating. Looking ahead, management raised its full-year organic revenue growth outlook to approximately 5.5% from 5.0%, and nudged its non-GAAP EPS guidance range to $5.62 to $5.66, with further acceleration expected in the back half of the fiscal year as the PFA franchise, Hugo robotic surgery system, and newly approved Altaviva therapy build commercial scale.